Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ir-CPI
Therapeutic Area : Hematology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Bioxodes Meets Enrollment Milestone for BIOX-101 in Intracerebral Hemorrhagic Stroke
Details : BIOX-101 (Ir-CPI) is a FXIa inhibitor small molecule drug candidate, which is being evaluated for the treatment of patients with intracerebral hemorrhagic stroke.
Brand Name : BIOX-101
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 27, 2024
Lead Product(s) : Ir-CPI
Therapeutic Area : Hematology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?